Home > News > Asklepios Bio and Bayer Healthcare Sign Research Deal
June 3rd, 2005
Asklepios Bio and Bayer Healthcare Sign Research Deal
Abstract:
Asklepios is currently conducting preclinical testing of a synthetically designed biological nano particle (BNP) gene therapy, containing the factor IX gene for the treatment of hemophilia B.
Source:
triangletechjournal.com
Bookmark:
| Related Links |
Asklepios Biopharmaceutical Inc.
| Related News Press |
Investments/IPO's/Splits
180 Degree Capital Corp. to Provide Live Remote Access to Its Annual Meeting of Shareholders on June 12, 2018 June 12th, 2018
Nanometrics Updates Time of Webcast at Stifel 2018 Cross Sector Insight Conference June 12th, 2018
Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences May 31st, 2018
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) March 20th, 2018
Nanomedicine
Nanobiotix Publishes Positive Phase 2/3 Data For Nanomedicine in Soft Tissue Cancer (Webcast June 22) June 22nd, 2018
Collaboration yields discovery of 12-sided silica cages June 20th, 2018
Announcements
Nanobiotix Publishes Positive Phase 2/3 Data For Nanomedicine in Soft Tissue Cancer (Webcast June 22) June 22nd, 2018
Collaboration yields discovery of 12-sided silica cages June 20th, 2018
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||